Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tylosin tartrate; testosterone propionate; oestradiol benzoate - parenteral implant, device - tylosin tartrate antibiotic active 29.0 mg; testosterone propionate steroid-anabolic active 200.0 mg; oestradiol benzoate steroid-estrogen active 20.0 mg - nutrition & metabolism - heifer - abscess | promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - testosterone propionate; oestradiol benzoate - parenteral implant, device - testosterone propionate steroid-anabolic active 200.0 mg/im; oestradiol benzoate steroid-estrogen active 20.0 mg/im - nutrition & metabolism - heifer (young female cattle) | bovine | cow young - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

United States - English - NLM (National Library of Medicine)

zoetis inc. - testosterone propionate (unii: wi93z9138a) (testosterone - unii:3xmk78s47o), estradiol benzoate (unii: 1s4cjb5zgn) (estradiol - unii:4ti98z838e) - testosterone propionate 200 mg - not for use in humans. keep out of reach of children. · for increased rate of weight gain and improved feed efficiency in growing beef heifers fed in confinement for slaughter. · other than as described on the labeling, this implant is not approved for repeated implantation (reimplantation) with any other cattle ear implant in growing beef heifers fed in confinement for slaughter as safety and effectiveness have not been evaluated. do not use in beef calves less than 2 months of age, dairy calves, and veal calves because effectiveness and safety have not been evaluated. do not use in animals intended for subsequent breeding, or in dairy cows.

United States - English - NLM (National Library of Medicine)

elanco us inc. - testosterone propionate (unii: wi93z9138a) (testosterone - unii:3xmk78s47o), estradiol benzoate (unii: 1s4cjb5zgn) (estradiol - unii:4ti98z838e), tylosin tartrate (unii: 5p4625c51t) (tylosin - unii:yef4jxn031) - each cartridge belt holds 20 doses of component e-h with tylan (testosterone and estradiol and tylosin implant) implants. each dose of 9 pellets consists of 8 pellets containing a total of 200 mg testosterone propionate usp and 20 mg estradiol benzoate plus 1 pellet containing 29 mg tylosin tartrate as a local antibacterial. component e-h (testosterone and estradiol implant) implants are recommended for use in heifers weighing 400 lbs or more for increased rate of weight gain and improved feed efficiency. do not use in veal calves. effectiveness and animal safety in veal calves have not been established.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - testosterone propionate; oestradiol benzoate; detectable marker - parenteral implant, device - testosterone propionate steroid-anabolic active 200.0 mg/im; oestradiol benzoate steroid-estrogen active 20.0 mg/im; detectable marker miscellaneous other 0.0 p - nutrition & metabolism - heifer (young female cattle) | bovine | cow young - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

United States - English - NLM (National Library of Medicine)

elanco animal health co - testosterone propionate (unii: wi93z9138a) (testosterone - unii:3xmk78s47o) - testosterone propionate 200 mg

United States - English - NLM (National Library of Medicine)

hospira, inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate 100 mg in 1 ml - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired )-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. hypogonadotropic hypogonadism (congenital or acquired )- gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate injection in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy) - patients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule iii controlled substan

United States - English - NLM (National Library of Medicine)

padagis us llc - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate 200 mg in 1 ml - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. safety and efficacy of testosterone cypionate in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. 1. known hypersensitivity to the drug 2. males with carcinoma of the breast 3. males with known or suspected carcinoma of the prostate gland 4. women who are pregnant (see precautions, pregnancy) 5. patients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule iii controlled substance in the controlled substances act. drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. abuse and misuse of testosterone are seen in male and female adults and adolescents. testosterone, often in combination with other anabolic androgenic steroids (aas), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. there have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. abuse-related adverse reactions serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. the following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. the following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. the following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. behaviors associated with addiction continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: • taking greater dosages than prescribed • continued drug use despite medical and social problems due to drug use • spending significant time to obtain the drug when supplies of the drug are interrupted • giving a higher priority to drug use than other obligations • having difficulty in discontinuing the drug despite desires and attempts to do so • experiencing withdrawal symptoms upon abrupt discontinuation of use physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate 100 mg in 1 ml - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired)- testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. hypogonadotropic hypogonadism (congenital or acquired)- gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy) - patients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule iii controlled substance in the c

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - testosterone propionate, quantity: 30 mg; testosterone phenylpropionate, quantity: 60 mg; testosterone isocaproate, quantity: 60 mg; testosterone decanoate, quantity: 100 mg - injection, solution - excipient ingredients: arachis oil; benzyl alcohol - indications as at 4 december 1996: androgen replacement therapy for confirmed testosterone deficiency in males.